GPT and blood coagulation disease: The AST/ALT ratio ≥ 1.8 or 1.9 accelerated the risk of 90-day adverse outcomes in patients with HBV-associated advanced fibrosis with severe jaundice and/or coagulopathy (Supplementary Figures S2A–C).